

Enrica Cavedo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8199610/publications.pdf>

Version: 2024-02-01

91
papers

7,970
citations

109321

35
h-index

71685

76
g-index

97
all docs

97
docs citations

97
times ranked

11410
citing authors

#	ARTICLE	IF	CITATIONS
1	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.8	1,318
2	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	7.4	1,166
3	The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. <i>Brain</i> , 2018, 141, 1917-1933.	7.6	1,008
4	Sex differences in Alzheimer disease – the gateway to precision medicine. <i>Nature Reviews Neurology</i> , 2018, 14, 457-469.	10.1	573
5	Brain atrophy in Alzheimer's Disease and aging. <i>Ageing Research Reviews</i> , 2016, 30, 25-48.	10.9	507
6	Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection. <i>Lancet Neurology</i> , The, 2015, 14, 1037-1053.	10.2	233
7	Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2019, 15, 465-476.	0.8	232
8	The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. <i>Alzheimer's and Dementia</i> , 2015, 11, 111-125.	0.8	162
9	Cognitive and neuroimaging features and brain β -amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. <i>Lancet Neurology</i> , The, 2018, 17, 335-346.	10.2	161
10	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. <i>Nature Reviews Neurology</i> , 2015, 11, 41-55.	10.1	144
11	Resting state cortical electroencephalographic rhythms are related to gray matter volume in subjects with mild cognitive impairment and Alzheimer's disease. <i>Human Brain Mapping</i> , 2013, 34, 1427-1446.	3.6	142
12	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	11.0	133
13	Revolution of Alzheimer Precision Neurology. <i>Passageway of Systems Biology and Neurophysiology. Journal of Alzheimer's Disease</i> , 2018, 64, S47-S105.	2.6	122
14	Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 764-775.	0.8	122
15	Cortex and amygdala morphology in psychopathy. <i>Psychiatry Research - Neuroimaging</i> , 2011, 193, 85-92.	1.8	118
16	Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1041-1049.	0.8	102
17	Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: $A\beta_{1-42}$, total τ , phosphorylated τ , NFL, neurogranin, and YKL40. <i>Alzheimer's and Dementia</i> , 2018, 14, 492-501.	0.8	91
18	Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 11706.	3.3	79

#	ARTICLE	IF	CITATIONS
19	Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. <i>Alzheimer's and Dementia</i> , 2018, 14, 1204-1215.	0.8	79
20	Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2017, 14, 285-299.	3.0	78
21	Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment. <i>The Cochrane Library</i> , 2020, 3, CD009628.	2.8	67
22	Medial temporal atrophy in early and late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 2004-2012.	3.1	59
23	Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. <i>Alzheimer's and Dementia</i> , 2017, 13, 454-467.	0.8	58
24	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.8	58
25	Cortical sources of resting state EEG rhythms are related to brain hypometabolism in subjects with Alzheimer's disease: an EEG-PET study. <i>Neurobiology of Aging</i> , 2016, 48, 122-134.	3.1	53
26	Striatal morphology in early-onset and late-onset Alzheimer's disease: a preliminary study. <i>Neurobiology of Aging</i> , 2013, 34, 1728-1739.	3.1	52
27	Resting State Cortical Electroencephalographic Rhythms and White Matter Vascular Lesions in Subjects with Alzheimer's Disease: An Italian Multicenter Study. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 331-346.	2.6	48
28	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. <i>Neurobiology of Aging</i> , 2019, 83, 42-53.	3.1	48
29	Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. <i>Neurochemistry International</i> , 2017, 108, 355-360.	3.8	46
30	Association of cerebrospinal fluid β -synuclein with total and phosphorylated τ 181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2018, 14, 1623-1631.	0.8	45
31	Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 940-950.	0.8	43
32	Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 993-1003.	0.8	39
33	Hippocampal and amygdalar volume changes in elderly patients with Alzheimer's disease and schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2011, 192, 77-83.	1.8	38
34	Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1631-e1638.	2.2	38
35	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2015, 6, 216.	2.4	36
36	Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1327-1334.	2.6	35

#	ARTICLE	IF	CITATIONS
37	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S171-S191.	2.6	34
38	Revolution of Resting-State Functional Neuroimaging Genetics in Alzheimer's Disease. <i>Trends in Neurosciences</i> , 2017, 40, 469-480.	8.6	34
39	Neurophysiological Assessment of Alzheimer's Disease Individuals by a Single Electroencephalographic Marker. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 159-177.	2.6	32
40	Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors. <i>Frontiers in Neurology</i> , 2018, 9, 642.	2.4	32
41	Disrupted white matter structural networks in healthy older adult APOE ϵ 4 carriers: An international multicenter DTI study. <i>Neuroscience</i> , 2017, 357, 119-133.	2.3	31
42	Relationship between Basal Forebrain Resting-State Functional Connectivity and Brain Amyloid- β Deposition in Cognitively Intact Older Adults with Subjective Memory Complaints. <i>Radiology</i> , 2019, 290, 167-176.	7.3	30
43	Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study. <i>Neurobiology of Aging</i> , 2020, 90, 43-59.	3.1	30
44	Brain β 2 load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2019, 15, 1274-1285.	0.8	25
45	Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 15.	6.2	24
46	Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease. <i>Neuropharmacology</i> , 2016, 108, 128-135.	4.1	23
47	Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 147.	6.2	23
48	The Italian Alzheimer's Disease Neuroimaging Initiative (I-ADNI): Validation of Structural MR Imaging. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 941-952.	2.6	22
49	In vivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 93, 98-108.	3.1	21
50	Effect of Alzheimer's disease risk and protective factors on cognitive trajectories in subjective memory complainers: An INSIGHT-preAD study. <i>Alzheimer's and Dementia</i> , 2018, 14, 1126-1136.	0.8	20
51	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. <i>Neurology</i> , 2020, 94, e30-e41.	1.1	20
52	Hippocampal and Amygdalar Local Structural Differences in Elderly Patients with Schizophrenia. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 47-58.	1.2	19
53	No association of cortical amyloid load and EEG connectivity in older people with subjective memory complaints. <i>NeuroImage: Clinical</i> , 2018, 17, 435-443.	2.7	19
54	Norms for Imaging Markers of Brain Reserve. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 623-633.	2.6	18

#	ARTICLE	IF	CITATIONS
55	Association of postoperative delirium with markers of neurodegeneration and brain amyloidosis: a pilot study. <i>Neurobiology of Aging</i> , 2018, 61, 93-101.	3.1	18
56	Association of plasma YKL-40 with brain amyloid- β^2 levels, memory performance, and sex in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020, 96, 22-32.	3.1	18
57	Cortical amyloid accumulation is associated with alterations of structural integrity in older people with subjective memory complaints. <i>Neurobiology of Aging</i> , 2017, 57, 143-152.	3.1	18
58	Efficacy of lifestyle interventions on clinical and neuroimaging outcomes in elderly. <i>Ageing Research Reviews</i> , 2016, 25, 1-12.	10.9	17
59	β -Secretase 1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 130.	6.2	16
60	Effects of rivastigmine on visual attention in subjects with amnesic mild cognitive impairment: A serial functional MRI activation pilot-study. <i>Psychiatry Research - Neuroimaging</i> , 2016, 249, 84-90.	1.8	10
61	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 543-555.	2.6	10
62	Plasma β -Secretase 1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2021, 17, 629-640.	0.8	10
63	Association of β -Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra. <i>Neurology</i> , 2022, 98, .	1.1	10
64	Validation of an automatic tool for the rapid measurement of brain atrophy and white matter hyperintensity: QyScore [®] . <i>European Radiology</i> , 2022, 32, 2949-2961.	4.5	9
65	Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 553-562.	3.7	8
66	Fully Automatic MRI-Based Hippocampus Volumetry Using FSL-FIRST: Intra-Scanner Test-Retest Stability, Inter-Field Strength Variability, and Performance as Enrichment Biomarker for Clinical Trials Using Prodromal Target Populations at Risk for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 151-164.	2.6	7
67	Randomized controlled trial on the efficacy of a multilevel non-pharmacologic intervention in older adults with subjective memory decline: design and baseline findings of the E.Mu.N.I. study. <i>Ageing Clinical and Experimental Research</i> , 2020, 32, 817-826.	2.9	6
68	White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 163-175.	2.6	5
69	Aptamer prediction of brain amyloid- β^2 status in cognitively normal individuals at risk for Alzheimer's disease. <i>PLoS ONE</i> , 2021, 16, e0243902.	2.5	5
70	Association of brain network dynamics with plasma biomarkers in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020, 88, 83-90.	3.1	4
71	[P4 ¹⁸⁴]: LOW COGNITIVE AWARENESS, BUT NOT COMPLAINT, IS A GOOD MARKER OF PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1333.	0.8	3
72	Ageing and sex impact plasma NFL and τ trajectories in individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e041792.	0.8	2

#	ARTICLE	IF	CITATIONS
73	Cognitive decline and cerebrospinal fluid biomarkers: a close relationship. <i>Future Neurology</i> , 2013, 8, 403-406.	0.5	1
74	[P2â€“379]: ACCURACY OF MRI CLASSIFICATION ALGORITHMS IN A TERTIARY MEMORY CENTER CLINICAL ROUTINE COHORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P772.	0.8	1
75	P3â€“218: NOVEL ALZHEIMER'S DISEASE BIOMARKERâ€“GUIDED DIAGNOSTIC WORKFLOW USING THE ADDED VALUE OF SIX COMBINED CEREBROSPINAL FLUID CANDIDATES: AÎ²_{1â€“42}, TOTALâ€“TAU, PHOSPHORYLATEDâ€“TAU, NFL, NEUROGRANIN, AND YKLâ€“40. <i>Alzheimer's and Dementia</i> , 2018, 14, P1154.	0.8	1
76	P1â€“431: APOEâ€“DEPENDENT LONGITUDINAL CHANGES IN DEFAULT MODE NETWORK FUNCTIONAL CONNECTIVITY IN SUBJECTIVE MEMORY COMPLAINERS. <i>Alzheimer's and Dementia</i> , 2018, 14, P474.	0.8	1
77	P4â€“072: INCREASED PLASMA BACE1 CONCENTRATIONS IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS: CORRELATION WITH PLASMA NFL. <i>Alzheimer's and Dementia</i> , 2018, 14, P1461.	0.8	0
78	P3â€“411: CLINICAL SIGNIFICANCE OF INâ€“VIVO STAGING OF REGIONAL AMYLOID DEPOSITION IN SUBJECTIVE MEMORY COMPLAINERS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1262.	0.8	0
79	P2â€“237: ASSOCIATION OF CSF ALPHAâ€“SYNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTICAL STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER'S DISEASE BIOMARKERS. <i>Alzheimer's and Dementia</i> , 2018, 14, P762.	0.8	0
80	O4â€“07â€“04: INCREASED RESILIENCE TO ALZHEIMER'S DISEASE PATHOPHYSIOLOGY IN MEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO WOMEN. <i>Alzheimer's and Dementia</i> , 2018, 14, P1419.	0.8	0
81	O3â€“09â€“02: CORRELATION AND LONGITUDINAL DYNAMICS OF PLASMA NFL AND TAU CONCENTRATIONS IN AMYLOIDâ€“PET NEGATIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1036.	0.8	0
82	P4â€“186: INNOVATIVE BIOMARKERâ€“GUIDED DIAGNOSTIC SYSTEM FROM PRECLINICAL TO ALZHEIMER'S DISEASE DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P1510.	0.8	0
83	P4â€“098: ASSOCIATION BETWEEN COGNITIVE RESERVE AND WHITE MATTER MICROSTRUCTURAL INTEGRITY IN OLDER ADULTS WITH SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1474.	0.8	0
84	P2â€“397: REDUCED BASAL FOREBRAIN FUNCTIONAL CONNECTIVITY IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO MEN. <i>Alzheimer's and Dementia</i> , 2018, 14, P855.	0.8	0
85	P2â€“246: INCREASED LONGITUDINAL DYNAMICS OF PLASMA YKLâ€“40 CONCENTRATIONS IN AMYLOIDâ€“PET POSITIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P767.	0.8	0
86	P2â€“249: CORRELATIONS AND ALTERED LONGITUDINAL DYNAMICS OF PLASMA BACE1 AND NFL CONCENTRATIONS IN INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P768.	0.8	0
87	P2â€“355: CORRELATION OF FUNCTIONAL MRI CONNECTOMES WITH PATHOPHYSIOLOGICAL ALZHEIMER'S PLASMA BIOMARKERS AND RISK FACTORS IN SUBJECTIVE MEMORY COMPLAINERS. <i>Alzheimer's and Dementia</i> , 2018, 14, P824.	0.8	0
88	Reply: Optimal use of cholinergic drugs in Alzheimerâ€™s disease. <i>Brain</i> , 2018, 141, e69.	7.6	0
89	Association of plasma YKLâ€“40 with brain amyloidosis, memory performance, and sex in subjective memory complainers. <i>Alzheimer's and Dementia</i> , 2020, 16, e041753.	0.8	0
90	Sensitivity and specificity of EEG biomarkers of AD at the preclinical stage. <i>Alzheimer's and Dementia</i> , 2020, 16, e045832.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Education and brain amyloid load act on temporal lobe function in individual with subjective memory complaint: An EEG&fMRI study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0